

Choice (Y/n) :

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST		0.42 1.07

FILE 'REGISTRY' ENTERED AT 15:16:57 ON 06 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4
 DICTIONARY FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\705bxxi.str

L3 STRUCTURE uploaded

=> s l3 sss sam
 SAMPLE SEARCH INITIATED 15:17:24 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 291 TO ITERATE

100.0% PROCESSED 291 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 4797 TO 6843
 PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l3 sss full
 FULL SEARCH INITIATED 15:17:37 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 5843 TO ITERATE

100.0% PROCESSED 5843 ITERATIONS 10 ANSWERS
 SEARCH TIME: 00.00.01

L5 10 SEA SSS FUL L3

=> FIL CAPLUS
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE
 ENTRY
 166.94

TOTAL
 SESSION
 168.01

FILE 'CAPLUS' ENTERED AT 15:17:46 ON 06 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11
 FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d 15 scan
 YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Butanedioic acid, [(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]-, 1-ethyl 4-[2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl] ester, (2Z)- (9CI)
 MF C28 H31 Cl N2 O9 S2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetic acid, [[[(17 β)-3,17-dihydroxyestra-1,3,5(10)-trien-6-ylidene]amino]oxy]-, 2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl ester (9CI)
 MF C28 H37 N3 O8 S

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [[3-[4-[(methoxymethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester, (S)- (9CI)
 MF C14 H19 N3 O7 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Thionitrous acid (HNOS), S-[1-[(2-hydroxyethyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI)
 MF C8 H14 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Thionitrous acid (HNOS), S-[1-methyl-1-(2-oxo-4-oxazolidinyl)ethyl] ester (9CI)
 MF C6 H10 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzenesulfonamide, 4-[(5-hydroxymethyl)-2-oxo-3-oxazolidinyl]-N-methoxy-, (R)- (9CI)
 MF C11 H14 N2 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Thionitrous acid (HNOS), S-[1-[3-(3-hydroxypropyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI)
 MF C9 H16 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, 3-[(4S)-4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester, (α S)- (9CI)
 MF C23 H28 N2 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetic acid, [(17β)-17-hydroxyestra-1,3,5(10)-trien-3-yl]oxy]-,
 2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl ester
 (9CI)
 MF C28 H38 N2 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzeneacetic acid, α -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, 3-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester, (α Z)- (9CI)
 MF C28 H31 F N2 O9 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> FIL HCAPLUS
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.46	169.37

FILE 'HCAPLUS' ENTERED AT 15:18:44 ON 06 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11
FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:14:42 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 15:14:54 ON 06 SEP 2006
L1 STRUCTURE uploaded
L2 0 S L1 SSS SAM

10/781,705

FILE 'HOME' ENTERED AT 15:15:38 ON 06 SEP 2006
 FILE 'REGISTRY' ENTERED AT 15:16:57 ON 06 SEP 2006

L3 STRUCTURE UPLOADED
 L4 0 S L3 SSS SAM
 L5 10 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:17:46 ON 06 SEP 2006
 FILE 'REGISTRY' ENTERED AT 15:18:00 ON 06 SEP 2006
 FILE 'CAPLUS' ENTERED AT 15:18:07 ON 06 SEP 2006
 FILE 'HCAPLUS' ENTERED AT 15:18:44 ON 06 SEP 2006


=> s 15
 L6 9 L5

=> d 16 ibib abs hitstr

L6 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:995933 HCAPLUS
 DOCUMENT NUMBER: 141:424343
 TITLE: Preparation of nitrosated and nitrosylated compounds
 for use in pharmaceutical compositions a nitric oxide
 (NO) donors
 INVENTOR(S): Earl, Richard A.; Garvey, David S.; Gaston, Ricky D.;
 Lin, Chia-En; Ranatunge, Ramani R.; Richardson,
 Stewart K.; Stevenson, Cheri A.
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: PCT Int. Appl., 181 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098538	A2	20041118	WO 2004-US7943	20040315
WO 2004098538	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004237574	A1	20041118	AU 2004-237574	20040315
CA 2518506	AA	20041118	CA 2004-2518506	20040315
EP 1603933	A2	20051214	EP 2004-749385	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2006009431	A1	20060112	US 2005-221901	20050909
PRIORITY APPLN. INFO.:			US 2003-453963P	P 20030313
			US 2003-482134P	P 20030625
			WO 2004-US7943	A 20040315

OTHER SOURCE(S): MARPAT 141:424343
 GI



AB Nitroso and nitrosyl derivs. of therapeutic agents, such as R-SNO, R-ONO, R-ONO₂ [R = antithrombogenic agent, thrombolytic agent, fibrinolytic agent, vasospasm inhibitor, potassium channel blocker, calcium channel blocker, antihypertensive agent, antimicrobial agent, antibiotic, platelet reducing agent, antimitotic agent, antiproliferative agent, microtubule inhibitor, antisecretory agent, remodeling inhibitor, antisense nucleotide, anticancer chemotherapeutic agent, steroid, nonsteroidal antiinflammatory agent, selective COX-2 inhibitor, immunosuppressive agent, growth factor antagonist or antibody, dopamine agonist, radiotherapeutic agent, heavy metal functioning as a radioplaque agent, biol. agent, aldosterone antagonist, α -adrenergic receptor antagonist, angiotensin II antagonist, β -adrenergic agonist, antihyperlipidemic drug, angiotensin converting enzyme (ACE) inhibitor, antioxidant, β -adrenergic antagonist, endothelin antagonist, neutral endopeptidase inhibitor, renin inhibitor, free radical scavenger, iron chelator, sex hormone, antipolymerase, antiviral agent, photodynamic therapy agent, antibody targeted therapy agent, gene therapy agent, etc.], were prepared for therapeutic use. The compds. and compns. of this invention can also be bound to a matrix. These nitroso- and nitro-compds. are claimed for use in treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathol. conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiol. conditions. The compds. of this invention are preferably estradiol compds., troglitazone compds., tranilast compds., retinoic acid compds., resveratrol compds., mycophenolic acid compds., acid compds., anthracenone compds. and trapidil compds. The cardiovascular diseases for treatment include restenosis, coronary artery disease, atherosclerosis, atherogenesis, cerebrovascular disease, angina, ischemic disease, congestive heart failure or pulmonary edema associated with acute myocardial infarction, aneurysm, thrombosis, hypertension, platelet adhesion, platelet aggregation, smooth muscle cell proliferation, a vascular or non-vascular complication associated with the use of a medical device, wounds associated with the use of a medical device, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, thrombocytopenia or a bleeding disorder. The autoimmune diseases for treatment include a pathol. condition resulting from abnormal cell proliferation, polycystic kidney disease, an inflammatory disease, for preserving an organ and/or a tissue or for inhibiting wound contraction in a patient. The pathol. conditions resulting from abnormal cell proliferation include is a cancer, a Karposi's sarcoma, a cholangiocarcinoma, a choriocarcinoma, a neoblastoma, a Wilm's tumor, Hodgkin's disease, a melanoma, multiple myelomas, a chronic lymphocytic leukemia or an acute or chronic granulocytic lymphoma. The inflammatory diseases for treatment includerheumatoid arthritis, an inflammatory skin

disease, restenosis, multiple sclerosis, a surgical adhesion, tuberculosis, a graft rejection, an inflammatory lung disease, an inflammatory bowel disease, an inflammatory disease that affects or causes obstruction of a body passageway, an inflammation of the eye, an inflammation of the nose, an inflammation of the throat or a neovascular diseases of the eye. Thus, S-mono- and O,S-dinitroso- β -estradiol derivs. I (R = NO, R1 = H, NO) were prepared via an esterification reaction of β -estradiol with 3-methyl-3-(2,4,6-trimethoxyphenylmethylthio)butyric acid using EDAP and DMAP in DMF to form mono-ester I [R = CH₂C₆H₂-2,4,6-(OMe)₃, R1 = H], cleavage of the trimethoxybenzyl S-protecting group of the mono-ester using L-cysteine and TFA in CH₂Cl₂ to give thiol I (R = R1 = H), and finally, treatment of the thiol with Bu nitrite in CH₂Cl₂ to form the desired S-mono- and O,S-dinitroso- β -estradiol derivs. The prepared compds. were assayed for suppression of proliferation of human coronary artery smooth muscle cells.

IT 794519-76-9P 794519-77-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrosated and nitrosylated compds. for use in pharmaceutical compns. as nitric oxide (NO) donors)


RN 794519-76-9 HCPLUS

CN Acetic acid, [[[[(17 β)-3,17-dihydroxyestra-1,3,5(10)-trien-6-ylidene]amino]oxy]-, 2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A




PAGE 2-A



RN 794519-77-0 HCPLUS

CN Acetic acid, [((17β) -17-hydroxyestra-1,3,5(10)-trien-3-yl]oxy]-,
 2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 346684-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nitrosated and nitrosylated compds. for use in pharmaceutical compns. as nitric oxide (NO) donors)

RN 346684-08-0 HCPLUS

CN Thionitrous acid (HNOS), S-[1-[3-(2-hydroxyethyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI) (CA INDEX NAME)



=> d 16 ibib abs hitstr 2-9

L6 ANSWER 2 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:836762 HCPLUS

DOCUMENT NUMBER: 139:350474

TITLE: Preparation and compositions of nitrosothio (hetero)cyclic nitric oxide donors

INVENTOR(S): Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Lin, Chia-en; Ranatunga, Ramani R.; Richardson, Stewart K.; Wang, Tiansheng; Wang, Weiheng; Wey, Shiow-jyi

PATENT ASSIGNEE(S): Nitromed, Inc., USA

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086282	A2	20031023	WO 2003-US10562	20030407
WO 2003086282	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480832	AA	20031023	CA 2003-2480832	20030407
AU 2003223491	A1	20031027	AU 2003-223491	20030407
US 2003203915	A1	20031030	US 2003-407420	20030407
EP 1497268	A2	20050119	EP 2003-719621	20030407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005537223	T2	20051208	JP 2003-583309	20030407
PRIORITY APPLN. INFO.:			US 2002-369873P	P 20020405
			WO 2003-US10562	W 20030407

OTHER SOURCE(S): MARPAT 139:350474

GI



AB Title compds. I [wherein U = O, S, or NR_aR_i; V = NO or NO₂; X₉ = CR₁₀ or N; Y₉ = CR₆R₇, NR_i, NR₂₅, NR_iCR₆R₇, CR₆R₇NR_i, CR₂R₃CR₆R₇, or CR₆R₇CR₂R₃; Y₁₀ = CR₈R₉ or CR₈R₉CR₁₇R₁₈; R₂-R₉, R₁₇, and R₁₈ = independently H or alkyl; or R₂R₃, R₄R₅, R₆R₇, or R₈R₉ = independently oxo; or R₄ and R₇ together with the C's to which they are attached = cycloalkyl; or CR₆R₇ = cycloalkyl; R₆ and R₉ taken together with the C's to which they are attached = (bridged)cycloalkyl, heterocyclyl, or aryl with the proviso that R₇ and R₈ are not present; R₄ and R₂₅ taken together with the C and N to which they are attached = heterocyclyl; Ra = lone pair of electrons, H, or (aryl)alkyl; Re and Rf = independently H, halo, OH, or (un)substituted


(cyclo)alkyl, heterocyclyl, alkoxy, amino, aryl, etc.; or CReRf = heterocyclyl or (bridged) cycloalkyl; Ri = H or (un)substituted alkyl, aryl, carboxamido, sulfonamido, etc.; n = 0-3; and pharmaceutically acceptable salts thereof] were prepared as novel nitric oxide donors for use in compns. comprising at least one nitric oxide donor and optionally at least one therapeutic agent. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiol. conditions (no data). For example, 2-[2-(nitrosothio)adamantan-2-yl]acetic acid was esterified with 3-nitrooxy-2,2-bis(nitrooxymethyl)propan-1-ol in the presence of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide•HCl and 4-dimethylaminopyridine in CH₂Cl₂ to give II (18%). The latter inhibited proliferation of human coronary artery smooth muscle cells with IC₅₀ of 5 μM. In general, the nitrosylated compds. tested in this assay inhibited proliferation of vascular smooth muscle cells, while the corresponding non-nitrosylated derivs. showed no inhibition, slight inhibition, or exhibited much higher IC₅₀ values. Thus, the invention provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathol. conditions resulting from abnormal cell proliferation, transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases, for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis (no data). The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders, and sexual dysfunctions (no data). In addition, the invention provides novel compns. and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

IT 346684-04-6 346684-08-0 375371-24-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition component; preparation and compns. of nitrosothio (hetero)cyclic nitric oxide donors for treatment of cardiovascular, proliferative, inflammatory, and autoimmune disorders and other conditions)


RN 346684-04-6 HCPLUS

CN Thionitrous acid (HNOS), S-[1-[3-(3-hydroxypropyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI) (CA INDEX NAME)




RN 346684-08-0 HCPLUS

CN Thionitrous acid (HNOS), S-[1-[3-(2-hydroxyethyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI) (CA INDEX NAME)



RN 375371-24-7 HCAPLUS
 CN Thionitrous acid (HNOS), S-[1-methyl-1-(2-oxo-4-oxazolidinyl)ethyl] ester
 (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:868945 HCAPLUS
 DOCUMENT NUMBER: 136:575
 TITLE: Infrared thermography and methods of use
 INVENTOR(S): Marek, Przemyslaw A.; Trocha, Andzrej M.
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001046471	A1	20011129	US 2001-850081	20010508
US 6762202	B2	20040713		
US 2004162243	A1	20040819	US 2004-781705	20040220
PRIORITY APPLN. INFO.:			US 2000-202935P	P 20000509
			US 2001-850081	A1 20010508

OTHER SOURCE(S): MARPAT 136:575

AB The present invention describes rapid noninvasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises the administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent to the patient followed by monitoring the temperature change of an area of interest using IR thermog. The present invention provides methods for diagnosing diseases or disorders related to vasodilation and changes in blood flow, such as, sexual dysfunction, Raynaud's syndrome, inflammation, hypertension, gastrointestinal disorders and central nervous system disorders. The sexual dysfunction is preferably female sexual dysfunction and female sexual arousal. The vasoactive agents include potassium channel activators, calcium channel blockers, α -adrenergic receptor antagonists, β -blockers, phosphodiesterase inhibitors, adenosine, ergot alkaloids, vasoactive intestinal peptides, prostaglandins, dopamine agonists, opioid antagonists, endothelin antagonists and thromboxane inhibitors. The present invention can also be used to screen and identify drug candidates for treating diseases, disorders and conditions resulting from vasodilation or changes in blood flow. The present invention also describes compns. comprising at least one S-nitrosothiol compound for diagnosing, monitoring and/or treating female sexual dysfunctions.

IT 375371-24-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IR thermog. for measuring vasodilation or changes in blood flow following administration of nitric oxide donor)

RN 375371-24-7 HCPLUS

CN Thionitrous acid (HNOS), S-[1-methyl-1-(2-oxo-4-oxazolidinyl)ethyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:721438 HCPLUS

DOCUMENT NUMBER: 135:288343

TITLE: Preparation and activity of nitrosated and

nitrosylated nonsteroidal antiinflammatory compounds

INVENTOR(S): Bandarage, Upul K.; Dong, Qing; Fang, Xinqin; Garvey, David S.; Mercer, Gregory J.; Richardson, Stewart K.; Schroeder, Joseph D.; Wang, Tiansheng

PATENT ASSIGNEE(S): Nitromed, Inc., USA

SOURCE: U.S., 59 pp., Cont.-in-part of U.S. Ser. No. 182,433, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6297260	B1	20011002	US 1999-429019	19991029
CA 2348741	AA	20000511	CA 1999-2348741	19991029
WO 2000025776	A1	20000511	WO 1999-US25481	19991029
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1126838	A1	20010829	EP 1999-958708	19991029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528495	T2	20020903	JP 2000-579217	19991029
AU 763000	B2	20030710	AU 2000-16012	19991029
US 2002016322	A1	20020207	US 2001-938560	20010827
US 6593347	B2	20030715		
US 2003207919	A1	20031106	US 2003-431457	20030508
AU 2004200091	A1	20040205	AU 2004-200091	20040109
PRIORITY APPLN. INFO.:			US 1998-182433	B2 19981030
			AU 2000-16012	A 19991029
			US 1999-429019	A3 19991029
			WO 1999-US25481	W 19991029
			US 2001-938560	A3 20010827

OTHER SOURCE(S) :
GI

MARPAT 135:288343



AB The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compds., and novel compns. comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders. Thus, I was prepared in 8 steps from cyclohexanecarboxaldehyde and shows a relative activity of 1, 1.2 and 0.02 in analgesic, antiinflammatory and gastric lesion tests.


IT 364056-07-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and activity of nitrosated and nitrosylated nonsteroidal antiinflammatory compds.)

RN 364056-07-5 HCPLUS

CN 2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, 3-[(4S)-4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester, (α S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2001:472491 HCPLUS

DOCUMENT NUMBER: 135:76524

TITLE: Preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors
 INVENTOR(S): Bandarage, Ramani R.; Bandarage, Upul K.; Fang, Xinqin; Garvey, David S.; Letts, L. Gordon; Schroeder, Joseph D.; Tam, Sang William
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: PCT Int. Appl., 230 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045703 6.28.01 A1	20010628	WO 2000-US35014	20001222	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393724	AA	20010628	CA 2000-2393724	20001222
US 2001041726	A1	20011115	US 2000-741816	20001222
US 6649629	B2	20031118		
EP 1246621	A1	20021009	EP 2000-989422	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017037	A	20030610	BR 2000-17037	20001222
JP 2003523958	T2	20030812	JP 2001-546642	20001222
NZ 519781	A	20040430	NZ 2000-519781	20001222
AU 782971	B2	20050915	AU 2001-25928	20001222
ZA 2002005707	A	20031111	ZA 2002-5707	20020717
US 2003220228	A1	20031127	US 2003-463671	20030618
PRIORITY APPLN. INFO.:			US 1999-171623P	P 19991223
			US 2000-226085P	P 20000818
			US 2000-741816	A3 20001222
			WO 2000-US35014	W 20001222

OTHER SOURCE(S): MARPAT 135:76524
GI



AB Title compds. were prepared. Thus, MeCOCH:CH₂ was condensed with 4-(MeS)C₆H₄CHO and the oxidized product cyclocondensed with Me₂C(SH)CH₂NH₂ to give, after Me₃CONO treatment, title compound I. Data for biol. activity of title compds. were given.

IT 346683-81-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors)

RN 346683-81-6 HCPLUS

CN Benzeneacetic acid, α -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, 3-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester, (α Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




IT 346684-04-6P 346684-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors)


RN 346684-04-6 HCPLUS

CN Thionitrous acid (HNOS), S-[1-[3-(3-hydroxypropyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI) (CA INDEX NAME)



RN 346684-08-0 HCPLUS

CN Thionitrous acid (HNOS), S-[1-[3-(2-hydroxyethyl)-2-oxo-4-oxazolidinyl]-1-methylethyl] ester (9CI) (CA INDEX NAME)



IT 346684-23-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors)

RN 346684-23-9 HCPLUS

CN Butanedioic acid, [(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]-, 1-ethyl 4-[2-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]ethyl] ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1989:8198 HCAPLUS
 DOCUMENT NUMBER: 110:8198
 TITLE: Preparation of (aminomethyl)phenyloxazolidinones as antibacterial agents
 INVENTOR(S): Gregory, Walter A.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
 SOURCE: U.S., 47 pp. Cont.-in-part of U.S. Ser. No. 676,745, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4705799	A	19871110	US 1985-803191	19851202
ZA 8404265	A	19860129	ZA 1984-4265	19840606
HU 196771	B	19890130	HU 1987-5132	19840606
IL 77230	A1	19900610	IL 1985-77230	19851204
CA 1275652	A2	19901030	CA 1988-580778	19881020
NO 8902178	A	19841210	NO 1989-2178	19890530
NO 169122	B	19920203		
NO 169122	C	19920513		
PRIORITY APPLN. INFO.:				
		US 1983-501897	A2	19830607
		US 1984-578332	A2	19840214
		US 1984-676745	A2	19841205
		CA 1984-455844	A3	19840605
		IL 1984-72028	A	19840605
		NO 1984-2273	A1	19840606

OTHER SOURCE(S): CASREACT 110:8198
 GI



AB The title compds. [I; A = NO₂, SH, alkylsulfonyl, -sulfinyl, -sulfenyl, etc.; B = N₃, (substituted) amino; Y = H, F, Cl, Br, alkyl, NO₂; or AY = O(CH₂)_nO where n = 1, 2, or 3], useful as antibacterial agents for mammals, are prepared. A mixture of I (A = 4-MeSO₂, B = OSO₂C₆H₄Me-4, Y = H) (preparation given) and NaN₃ in DMF was heated at 90-100° for 1 h to give I (A = 4-MeSO₂, B = N₃, Y = H). II showed a minimal inhibition concentration of 6.3 µg/mL against *Staphylococcus epidermidis*.


IT 96800-39-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial agent)

RN 96800-39-4 HCPLUS

CN Carbamic acid, [(3-[4-[(methoxymethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1985:437470 HCPLUS

DOCUMENT NUMBER:

103:37470

TITLE:

Aminomethyloxooxazolidinylbenzene derivatives useful as antibacterial agents

INVENTOR(S):

Gregory, Walter Adelman

PATENT ASSIGNEE(S):

du Pont de Nemours, E. I., and Co., USA

SOURCE:

Eur. Pat. Appl., 85 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

3

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.


DATE

EP 127902	A2	19841212	EP 1984-106400	19840605
EP 127902	A3	19870902		
EP 127902	B1	19911016		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ES 533097	A1	19850801	ES 1984-533097	19840604
AU 8429099	A1	19841213	AU 1984-29099	19840605
AU 583250	B2	19890427		
IL 72028	A1	19880531	IL 1984-72028	19840605
CA 1254213	A1	19890516	CA 1984-455844	19840605
AT 68490	E	19911115	AT 1984-106400	19840605
DK 8402795	A	19841208	DK 1984-2795	19840606
FI 8402273	A	19841208	FI 1984-2273	19840606
FI 83216	B	19910228		
FI 83216	C	19910610		
NO 8402273	A	19841210	NO 1984-2273	19840606
NO 163451	B	19900219		
NO 163451	C	19900530		
JP 60008277	A2	19850117	JP 1984-114710	19840606
HU 34462	A2	19850328	HU 1984-2192	19840606
HU 194194	B	19880128		
ZA 8404265	A	19860129	ZA 1984-4265	19840606
HU 196771	B	19890130	HU 1987-5132	19840606
SU 1505442	A3	19890830	SU 1984-3752502	19840606
ES 540812	A1	19880316	ES 1985-540812	19850228
SU 1426451	A3	19880923	SU 1986-4024095	19860207
CA 1275652	A2	19901030	CA 1988-580778	19881020
NO 8902178	A	19841210	NO 1989-2178	19890530
NO 169122	B	19920203		
NO 169122	C	19920513		

PRIORITY APPLN. INFO.:

US 1983-501897	A	19830607
US 1984-578332	A	19840214
CA 1984-455844	A3	19840605
EP 1984-106400	A	19840605
NO 1984-2273	A1	19840606

GI



AB The bactericidal oxazolidinones I [R = e.g. NO₂, cyano, HO, HS, (un)substituted amines, alkylsulfonyl, alkylthio, alkylsulfinyl, aryl, sulfamoyl, alkoxy, or carbamoyl; R₁ = H, F, Cl, Br, NO₂; RR₁ = alkyleneoxy, R₂ = NH₂, acylamino, N₃, alkylsulfonylamino, alkylsulfinylamino] and their physiol. acceptable salts were prepared. Thus, (\pm)-I (R = 4-MeSO₂, R₁ = H, R₂ = Cl) was treated with NaI and the resulting (\pm)-I (R₂ = iodo) treated with NaN₃ followed by hydrogenation in F₃CCO₂H to give (\pm)-I (R = 4-MeSO₂; R₁ = H, R₂ = NH₂).F₃CCO₂H (II). The min. inhibitory concentration of II was 50 μ g/mL against *Staphylococcus epidermidis*.

IT 96800-39-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of)

RN 96800-39-4 HCAPLUS

CN Carbamic acid, [[3-[4-[(methoxymethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1984:611126 HCPLUS

DOCUMENT NUMBER:

101:211126

TITLE:

p-Oxooxazolidinylbenzene compounds as antibacterial agents

INVENTOR(S):

Gregory, Walter A.

PATENT ASSIGNEE(S):

du Pont de Nemours, E. I., and Co., USA

SOURCE:

U.S., 21 pp. Cont.-in-part of U.S. Ser. No. 417,569, abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4461773	A	19840724	US 1984-567411	19840105
AU 8291032	A1	19830609	AU 1982-91032	19821201
AU 560666	B2	19870416		
ES 517852	A1	19840116	ES 1982-517852	19821201
ZA 8208872	A	19840725	ZA 1982-8872	19821202
CA 1182824	A1	19850219	CA 1982-416882	19821202
IL 67397	A1	19870331	IL 1982-67397	19821202
DK 8205383	A	19830605	DK 1982-5383	19821203
FI 8204182	A	19830605	FI 1982-4182	19821203
FI 78078	B	19890228		
FI 78078	C	19890612		
NO 8204072	A	19830606	NO 1982-4072	19821203
NO 156751	B	19870810		
NO 156751	C	19871202		
JP 58103376	A2	19830620	JP 1982-211542	19821203
JP 04016471	B4	19920324		
HU 29080	O	19840130	HU 1982-3896	19821203
HU 189196	B	19860630		
HU 32542	O	19840828	HU 1983-3543	19821203
HU 186807	B	19850930		
SU 1194274	A3	19851123	SU 1982-3519552	19821203


PRIORITY APPLN. INFO.:

US 1981-327583
US 1982-417569A2 19811204
A2 19820915

OTHER SOURCE(S) :

CASREACT 101:211126

GI



AB Phenyloxazolidinones I [R = SO₂N₃, SO₂NHNH₂, (un)substituted sulfamoyl, carbamoyl, CR₂:NR₃; R₁ = H, alkyl, acyl, aminoacyl, carboxyacyl, HO₂CCH:CHCO, 2-carboxycyclohexanecarbonyl, 2-carboxycyclohexenecarbonyl; R₂ = H, alkyl, cycloalkyl; R₃ = amino, OR₂] were prepared. Thus, 1-I (R = MeS, R₁ = H) was dethiolated using Raney-Ni to give I (R = R₁ = H) which was trifluoroacetylated and chlorosulfonylated to give 1-I (R = ClSO₂, R₁ = COCF₃). The latter compound was treated with NH₃ to give 1-I (R = H₂NSO₂, R₁ = H), which had a min. inhibitory concentration against Escherichia coli of 29.8 µg/mL and an oral ED₅₀ in mice against E. coli of 13.2 mg/kg.


IT 87472-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 87472-15-9 HCPLUS

CN Benzenesulfonamide, 4-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-N-methoxy-, (R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1984:51564 HCPLUS

DOCUMENT NUMBER:

100:51564

TITLE:

p-Oxooxazolidinylbenzenesulfonamides as antibacterial agents

INVENTOR(S) :

Gregory, Walter Adelman

PATENT ASSIGNEE(S) :

du Pont de Nemours, E. I., and Co. , USA

SOURCE:

Eur. Pat. Appl., 52 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 81200	A1	19830615	EP 1982-111135	19821202
EP 81200	B1	19861008		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8291032	A1	19830609	AU 1982-91032	19821201
AU 560666	B2	19870416		
ES 517852	A1	19840116	ES 1982-517852	19821201
ZA 8208872	A	19840725	ZA 1982-8872	19821202
CA 1182824	A1	19850219	CA 1982-416882	19821202
AT 22686	E	19861015	AT 1982-111135	19821202
IL 67397	A1	19870331	IL 1982-67397	19821202
DK 8205383	A	19830605	DK 1982-5383	19821203
FI 8204182	A	19830605	FI 1982-4182	19821203
FI 78078	B	19890228		
FI 78078	C	19890612		
NO 8204072	A	19830606	NO 1982-4072	19821203
NO 156751	B	19870810		
NO 156751	C	19871202		
JP 58103376	A2	19830620	JP 1982-211542	19821203
JP 04016471	B4	19920324		
HU 29080	O	19840130	HU 1982-3896	19821203
HU 189196	B	19860630		
HU 32542	O	19840828	HU 1983-3543	19821203
HU 186807	B	19850930		
SU 1194274	A3	19851123	SU 1982-3519552	19821203
PRIORITY APPLN. INFO.:			US 1981-327583	A 19811204
			US 1982-417569	A 19820915
			EP 1982-111135	A 19821202

OTHER SOURCE(S) :

MARPAT 100:51564

GI



AB Oxazolidinones I [R = (un)substituted amino, N3, NHNH2, N:S(O)nR1R2; R1, R2 = alkyl; R1R2 = alkylene; R3 = H, COC6H4CO2H-2, COCH:CHCO2H, acyl; n = 0, 1] were prepared. Thus PhNHCH2CH(OH)CH2OH was resolved and the d-isomer was cyclized with (EtO)2CO to give oxazolidinone 1-II. 1-II was esterified and treated with ClSO3H to give 1-I (R = Cl, R3 = COCF3) which gave 1-I (R = NH2, R3 = H) (1-III) on treatment with NH3. 1-III had a min. inhibitory concentration of 29.8 µg/mL against Escherichia coli.

IT 87472-15-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87472-15-9 HCPLUS

CN Benzenesulfonamide, 4-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-N-methoxy-, (R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.